TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results

TG Therapeutics (NASDAQ:TGTX) posted its quarterly earnings results on Monday. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06, Zacks reports. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

TG Therapeutics Stock Up 5.5 %

TGTX opened at $30.09 on Monday. The firm has a market capitalization of $4.68 billion, a P/E ratio of -300.87 and a beta of 2.26. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a fifty day moving average price of $30.75 and a 200-day moving average price of $28.14. TG Therapeutics has a one year low of $12.93 and a one year high of $36.84.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. upped their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday, January 15th. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, StockNews.com cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $40.67.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares of the company’s stock, valued at $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.50% of the stock is currently owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.